Literature DB >> 2387584

Genomic organization of human complement component C3.

K Y Fong1, M Botto, M J Walport, A K So.   

Abstract

Six overlapping clones, spanning the entire C3 gene and the 5' flanking region, were isolated from two genomic lambda libraries. Thirty exons, covering the complete beta chain and part of the alpha chain as far as the C3d region, were analyzed. The full exon-intron organization of the gene was deduced by combining our data with the reported organization of the alpha' chain (Barnum et al., 1989, J. Biol. Chem. 264: 8471-8474). The complete gene is 41 kb and consists of 41 exons. The C3 beta chain spans 13 kb from exon 1 to exon 16. Exon 16 encodes both alpha and beta chains. The alpha chain is 28 kb and contains 26 exons, including exon 16. The 5' flanking region was sequenced up to 514 bases upstream from the ATG start site. The major transcription initiation site was mapped to an adenine residue 61 bases upstream from the signal peptide by primer extension analysis of poly(A)+ mRNA from hepatocytes and U937 cells. The TATA box motif was assigned at position -85. Several putative binding sites for transcription factors were found in the 5' flanking region, suggesting possible pathways for the regulation of the C3 gene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387584     DOI: 10.1016/0888-7543(90)90202-6

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  9 in total

1.  Cis- and trans-acting elements required for constitutive and cytokine-regulated expression of the mouse complement C3 gene.

Authors:  N Kawamura; L Singer; R A Wetsel; H R Colten
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

2.  A 58-base-pair region of the human C3 gene confers synergistic inducibility by interleukin-1 and interleukin-6.

Authors:  D R Wilson; T S Juan; M D Wilde; G H Fey; G J Darlington
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

3.  Molecular basis of hereditary C3 deficiency.

Authors:  M Botto; K Y Fong; A K So; A Rudge; M J Walport
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

4.  Homozygous hereditary C3 deficiency due to a partial gene deletion.

Authors:  M Botto; K Y Fong; A K So; R Barlow; R Routier; B J Morley; M J Walport
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

5.  Molecular characterization of the pig C3 gene and its association with complement activity.

Authors:  Klaus Wimmers; Supamit Mekchay; Karl Schellander; Siriluck Ponsuksili
Journal:  Immunogenetics       Date:  2003-01-09       Impact factor: 2.846

6.  Nonsense-codon-mediated decay in human hereditary complement C3 deficiency.

Authors:  Edimara S Reis; Victor Nudelman; Lourdes Isaac
Journal:  Immunogenetics       Date:  2003-11-25       Impact factor: 2.846

7.  Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.

Authors:  Veronique Frémeaux-Bacchi; Elizabeth C Miller; M Kathryn Liszewski; Lisa Strain; Jacques Blouin; Alison L Brown; Nadeem Moghal; Bernard S Kaplan; Robert A Weiss; Karl Lhotta; Gaurav Kapur; Tej Mattoo; Hubert Nivet; William Wong; Sophie Gie; Bruno Hurault de Ligny; Michel Fischbach; Ritu Gupta; Richard Hauhart; Vincent Meunier; Chantal Loirat; Marie-Agnès Dragon-Durey; Wolf H Fridman; Bert J C Janssen; Timothy H J Goodship; John P Atkinson
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

8.  Mutations in CPAMD8 Cause a Unique Form of Autosomal-Recessive Anterior Segment Dysgenesis.

Authors:  Sek-Shir Cheong; Lisa Hentschel; Alice E Davidson; Dianne Gerrelli; Rebecca Davie; Roberta Rizzo; Nikolas Pontikos; Vincent Plagnol; Anthony T Moore; Jane C Sowden; Michel Michaelides; Martin Snead; Stephen J Tuft; Alison J Hardcastle
Journal:  Am J Hum Genet       Date:  2016-11-10       Impact factor: 11.025

9.  Molecular basis of polymorphisms of human complement component C3.

Authors:  M Botto; K Y Fong; A K So; C Koch; M J Walport
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.